Abstract
Aim of the study was to analyse the Ministry of Health’s (MINSAL) administrative database of the Universal Health Coverage (UHC) program for First Episode of Schizophrenia Spectrum Disorders (FEP-SSD). The database included every case registered in the program between 2004 and 2017. According to the timeframes established for permanence in the program, cases were defined as Suspected, FEP in diagnostic observation and FEP-SSD. Only first registers were analysed. We compared gender, age at entry, level of care and region where the case was registered. Denominator data for estimation of incidence rates were obtained from the last census. We adjusted incidence rate ratios by age, gender, and region. During the studied period, 33.207 suspected cases were registered. 27.006 (81%) were confirmed as FEP and after 6-month follow-up, 22.701 (68%) were confirmed as FEP-SSD. The median age at entry was 24 years, males entering at younger age. Male proportion was higher than female in all groups. 46.9% of all cases were detected in primary care. FEP-SSD cases were six years younger and had a higher proportion of males than discarded cases (62.6 vs 53.2%). During 169.4 million person-years at risk, crude incidence for suspected cases was 19.58 per 100.000 person-years; for FEP, 15.92 per 100.000 person-years and for FEP-SSD, 13.38 per 100.000 person-years. Chile has lower incidence of FEP-SSD compared to current world estimations but gender proportions are comparable. This UHC program has allowed early access through the integration of mental health to the health network at all levels of care.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the Ministry of Health, Government of Chile. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of the Ministry of Health, Government of Chile.
References
Whiteford HA, Degenhardt L, Rehm J et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586. https://doi.org/10.1016/S0140-6736(13)61611-6
Lora A, Kohn R, Levav I et al (2012) Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bull World Health Organ 90:47-54B. https://doi.org/10.2471/BLT.11.089284
Jesus Mari J, Tófoli LF, Noto C et al (2013) Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies. Drugs 73:1549–1568. https://doi.org/10.1007/s40265-013-0113-4
O’Connell T, Rasanathan K, Chopra M (2014) What does universal health coverage mean? Lancet 383:277–279. https://doi.org/10.1016/S0140-6736(13)60955-1
Patel V (2016) Universal health coverage for schizophrenia: a global mental health priority. Schizophr Bull 42:885–890. https://doi.org/10.1093/schbul/sbv107
Aguilera X, Castillo-Laborde C, Ferrari MN-D et al (2014) Monitoring and evaluating progress towards universal health coverage in Chile. PLoS Med 11:e1001676. https://doi.org/10.1371/journal.pmed.1001676
Minoletti A, Soto-Brandt G, Sepúlveda R et al (2018) Mental health response capacity in primary care in Chile: a contribution to Alma-Ata. Revista Panamericana de Salud Pública https://doi.org/10.26633/RPSP.2018.136
Salud MD (2004) LEY-19966 03-SEP-2004 MINISTERIO DE SALUD. In: Ley Chile - Biblioteca del Congreso Nacional. https://www.leychile.cl/Navegar?idNorma=229834. Accessed 7 Sep 2017
Markkula N, Alvarado R, Minoletti A (2011) Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia. PS 62:1463–1469. https://doi.org/10.1176/appi.ps.001042011
Ministerio de Salud (2005) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia
Ministerio de Salud (2009) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia
Ministerio de Salud (2017) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia
Goldner EM, Hsu L, Waraich P, Somers JM (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833–843. https://doi.org/10.1177/070674370204700904
Vicente B, Kohn R, Rioseco P et al (2006) Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry 163:1362–1370
González-Valderrama A, Jongsma HE, Mena C et al (2020) The incidence of non-affective psychotic disorders in Chile between 2005 and 2018: results from a national register of over 30000 cases. Psychological Med. https://doi.org/10.1017/S0033291720002664
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
Jablensky A (2010) The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci 12:271–287
Davidson LL, Grigorenko EL, Boivin MJ et al (2015) A focus on adolescence to reduce neurological, mental health and substance-use disability. Nature 527:S161–S166. https://doi.org/10.1038/nature16030
Reinhardt MM, Cohen CI (2015) Late-life psychosis: diagnosis and treatment. Curr Psychiatry Rep. https://doi.org/10.1007/s11920-014-0542-0
Instituto Nacional de Estadísticas (2019) Censos de Población y Vivienda - Censo 2017. https://www.ine.cl/estadisticas/censos/censos-de-poblacion-y-vivienda. Accessed 28 Aug 2019
Vandenbroucke JP, Pearce N (2012) Incidence rates in dynamic populations. Int J Epidemiol 41:1472–1479. https://doi.org/10.1093/ije/dys142
I Nacional de Estadisticas (Santiago de Chile) (2008) División político administrativa y censal 2007. Instituto Nacional de Estadísticas, Santiago (Chile)
StataCorp (2019) Stata statistical software: release 16. StataCorp LLC., College Station, TX
Del-Ben CM, Shuhama R, Loureiro CM et al (2019) Urbanicity and risk of first-episode psychosis: incidence study in Brazil. Br J Psychiatry. https://doi.org/10.1192/bjp.2019.110
Castillejos MC, Martín-Pérez C, Moreno-Küstner B (2018) A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. Psychol Med 48:2101–2115. https://doi.org/10.1017/S0033291718000235
Jongsma HE, Turner C, Kirkbride JB, Jones PB (2019) International incidence of psychotic disorders, 2002–17: a systematic review and meta-analysis. The Lancet Public Health 4:e229–e244. https://doi.org/10.1016/S2468-2667(19)30056-8
Eyheramendy S, Martinez FI, Manevy F et al (2015) Genetic structure characterization of Chileans reflects historical immigration patterns. Nat Commun 6:1–10. https://doi.org/10.1038/ncomms7472
Häfner H, Maurer K, Löffler W, Riecher-Rössler A (1993) The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80–86. https://doi.org/10.1192/bjp.162.1.80
Thorup A, Waltoft BL, Pedersen CB et al (2007) Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med 37:479. https://doi.org/10.1017/S0033291707009944
Häfner H (2019) From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry Journal https://www.hindawi.com/journals/psychiatry/2019/9804836/. Accessed 7 Sep 2020
Jongsma HE, Gayer-Anderson C, Lasalvia A et al (2018) Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiat 75:36. https://doi.org/10.1001/jamapsychiatry.2017.3554
Patel V, Saxena S (2019) Achieving universal health coverage for mental disorders. BMJ 366:l4516. https://doi.org/10.1136/bmj.l4516
Inter-American Drug Abuse Control Commission (2019) Informe sobre el consumo de drogas en las Américas, 2019 / Comisión Interamericana para el Control del Abuso de Drogas
Observatorio Chileno de Drogas, Servicio Nacional para la Prevención y Rehabilitación del Consumo de Drogas y Alcohol, SENDA, Gobierno de Chile (2018) Décimo Segundo Estudio Nacional de Drogas en Población Escolar de Chile, 2017 8o Básico a 4o Medio
Marconi A, Di Forti M, Lewis CM et al (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269. https://doi.org/10.1093/schbul/sbw003
Di Forti M, Quattrone D, Freeman TP et al (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6:427–436. https://doi.org/10.1016/S2215-0366(19)30048-3
Anderson KK, Fuhrer R, Malla AK (2010) The pathways to mental health care of first-episode psychosis patients: a systematic review. Psychol Med 40:1585–1597. https://doi.org/10.1017/S0033291710000371
Fett A-KJ, Lemmers-Jansen ILJ, Krabbendam L (2019) Psychosis and urbanicity. Curr Opin Psychiatry 32:232–241. https://doi.org/10.1097/YCO.0000000000000486
McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76. https://doi.org/10.1093/epirev/mxn001
Anderson KK (2013) Health service registry data in psychiatric epidemiology: challenges for definition and interpretation: an editorial comment to: Okkels et al’.s ‘Changes in the diagnosed incidence of early onset schizophrenia over four decades’ (1). Acta Psychiatr Scand 127:9–10. https://doi.org/10.1111/j.1600-0447.2012.01916.x
Anderson KK (2019) Towards a public health approach to psychotic disorders. Lancet Public Health 4:e212–e213. https://doi.org/10.1016/S2468-2667(19)30054-4
Hogerzeil SJ, van Hemert AM (2019) Design choices when estimating the treated incidence of schizophrenia. Psychol Med. https://doi.org/10.1017/S0033291719001338
Möller H-J (2009) Standardised rating scales in Psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6–26. https://doi.org/10.1080/15622970802264606
Williams J, Farmer AE, Ackenheil M et al (1996) A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med 26:775–783. https://doi.org/10.1017/S003329170003779X
Parnas J (2015) Differential diagnosis and current polythetic classification. World Psychiatry 14:284–287. https://doi.org/10.1002/wps.20239
Rasmussen AR, Nordgaard J, Parnas J (2020) Schizophrenia-spectrum psychopathology in obsessive–compulsive disorder: an empirical study. Eur Arch Psychiatry Clin Neurosci 270:993–1002. https://doi.org/10.1007/s00406-019-01022-z
Zandersen M, Parnas J (2020) Exploring schizophrenia spectrum psychopathology in borderline personality disorder. Eur Arch Psychiatry Clin Neurosci 270:969–978. https://doi.org/10.1007/s00406-019-01039-4
Freudenreich O, Schulz SC, Goff DC (2009) Initial medical work-up of first-episode psychosis: a conceptual review. Early Interv Psychiatry 3:10–18. https://doi.org/10.1111/j.1751-7893.2008.00105.x
Lieberman JA, First MB (2018) Psychotic Disorders. N Engl J Med 379:270–280. https://doi.org/10.1056/NEJMra1801490
Funding
Authors are paid staff of Universidad Andres Bello (VL, LV, GV), MINSAL (MI, VH, RC) and Universidad de Santiago (IR), and received no specific funding for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they do not have any conflict of interest.
Ethical approval
The Research Bioethics Committee of Universidad Andres Bello granted permission to conduct the study (Certificate of Approval 020/2019).
Informed consent for publication
All authors have consented to publish this research report.
Rights and permissions
About this article
Cite this article
Larach, V., Varela, L.F., Vergara, G. et al. Universal healthcare coverage for first episode of schizophrenia-spectrum disorders in Chile: analysis of the administrative database. Eur Arch Psychiatry Clin Neurosci 272, 129–138 (2022). https://doi.org/10.1007/s00406-021-01254-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-021-01254-y